New York, NY (US) – February 29, 2012 — Royalty Pharma announced today that it has acquired certain rights to receive royalties on future worldwide net sales of Cimzia® and Mircera® for an aggregate cash payment of $124 million.
Cimzia, marketed by UCB and launched in the United States and the European Union in 2009, is an anti-TNF biologic, which has been approved for the treatment of Crohn’s disease in the United States and for the treatment of rheumatoid arthritis in the United States and in the European Union. Cimzia blocks the action of tumor necrosis factor-alpha, a protein that plays a role in causing inflammation in rheumatoid arthritis. Cimzia generated 2011 sales of $423 million, a 65% year-on-year growth compared to 2010.
Mircera, marketed by Roche and launched in 2007 in the European Union, is a novel continuous erythropoietin receptor activator indicated for the treatment of anemia associated with chronic kidney disease. This condition – which affects patients on dialysis, as well as subset of patients not on dialysis – occurs when kidney functions become impaired, primarily due to diabetes, high blood pressure or injury. The product has been approved in the United States and pursuant to a settlement and limited license agreement with Amgen, Roche may begin selling Mircera in the United States in 2014. Mircera generated 2011 sales of $382 million in the European Union, Japan and a number of other markets, a 51% year-on-year growth compared to 2010.
Pablo Legorreta, Chief Executive Officer of Royalty Pharma, stated, “We are pleased to acquire these products which are both leaders in their respective treatment categories and will complement our existing portfolio of leading biopharmaceutical royalties.”
About Royalty Pharma
Royalty Pharma is the industry leader in acquiring revenue-producing intellectual property, principally royalty interests in marketed and late stage biopharmaceutical products. Royalty Pharma currently owns a diversified portfolio of royalty interests in several high-quality blockbuster biopharmaceutical products with a market value of over $6 billion. Portfolio products include Amgen’s Neupogen® and Neulasta® , Genentech’s Rituxan® , Gilead’s Emtriva® , Truvada® and Atripla® , Celgene’s Thalomid® , Abbott’s Humira® , J&J’s Remicade® , Pfizer’s Lyrica® , Gilead’s Letairis® , GlaxoSmithKline’s Volibris® , Genzyme’s Myozyme® , Merck’s Januvia® /Janumet®, Novartis’ Galvus® and Eli Lilly’s Tradjenta® . The company has a fifteen year history of providing value to holders of royalty interests, including its joint $525 million acquisition with Gilead Sciences of Emory University’s emtricitabine royalty interest, its acquisitions of approximately 80% of Memorial Sloan-Kettering’s US, international royalty interests in Neupogen® and Neulasta® for over $400 million and its $670 million acquisition of AstraZeneca’s Humira royalty interest and most recently its $609 million acquisition of Astellas Pharma’s patent estate and associated royalty stream relating to the use of dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes. More information on Royalty Pharma is available at www.royaltypharma.com
For more information:
Royalty Pharma | RP Management LLC
+1 (212) 883-0200